5 Best Fast Growth Stocks to Buy Now

4. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Number of Hedge Fund Holders: 29  

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is a biopharma firm that develops drugs for the treatment of cancer. The company recently announced that it had obtained regulatory approval in Europe for Qinlock, a drug for the treatment of gastrointestinal stromal tumors.

HC Wainwright analyst Andrew Fein has a Buy rating on Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) stock with a price target of $15. In a recent investor note, the analyst appreciated the decision of the pharma firm to streamline commercial operations. 

At the end of the third quarter of 2021, 29 hedge funds in the database of Insider Monkey held stakes worth $493 million in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), up from 23 in the previous quarter worth $568 million.